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ABSTRACT  
Objective: The present aim of this study was to formulate, optimize and evaluation of floating tablets of Clarithromycin.  
Methods: Floating tablets of Clarithromycin were formulated using polymer HPMC K15M with sodium bicarbonate as gas generating agent by wet 
granulation method. A 32 factorial design were applied to systematically optimize the drug release profile. The amount of citric acid (X1) and 
concentration of polymer HPMC K15M (X2
Keywords: Floating tablets, Gastric retention, Clarithromycin, Factorial design. 
) was selected as independent variables. The drug release at 6 hours (Q6) and drug release at 12 hour 
(Q12), and diffusion exponent (n) was selected as dependent variables. 
Results: The results of factorial design indicated that low level of HPMC K15M favors the preparation of floating controlled release of 
Clarithromycin tablets. The tablets were evaluated for thickness, hardness, weight variation, floating lag time, total floating time, swelling index, 
drug content uniformity and in vitro drug release in 0.1N HCL (pH 1.2). The in vitro dissolution profiles of all the prepared Clarithromycin floating 
drug delivery system formulations was found to extend the drug release over a period of 10 to 12 hours and the drug release rate decreased with 
increase in polymer concentration. 
Conclusion: It can be concluded that the decreased in citric acid concentration in the formulation showed decreased in drug release, this is due to 
citric acid reaction with sodium bicarbonate resulting generation of carbon dioxide gas at a faster rate, increased rate of drug release. Increasing the 
concentration of HPMC K15M resulted in reduction of drug release. 
 
INTRODUCTION  
Oral route is the most convenient and extensively used route for 
drug administration. This route has high patient acceptability, 
primarily due to ease of administration. Over the year, oral dosage 
forms have become increasingly sophisticated with the major role 
being played by controlled release drug delivery system (CRDDS) 
[1, 2]. Drug that are easily absorbed from the gastro-intestinal tract 
(GIT) and having a short half life are eliminated quickly from the 
blood circulation. To avoid this problem, the oral controlled release 
formulations have been developed, as these will release the drug 
slowly into the GIT and maintain a constant drug concentration in 
the serum for a longer period of time. One of the feasible approaches 
to control the gastric residence time (GRT).  
Gastro retentive dosage forms significantly extend the period of time 
over which drug may be released and thus prolong dosing intervals 
and increase patient compliance. Such retention systems are 
important for drug that are degraded in the intestine or for drug like 
antacids or certain antibiotics, enzymes that act locally in the 
stomach if the drug are poorly soluble in the intestine due to alkaline 
pH and then its retention in the gastric region may increase the 
solubility before they are emptied, resulting in increased 
bioavailability [3, 4]. Dosage forms with prolonged gastric residence 
time (GRT), i.e. Gastro-remaining or gastro retentive dosage forms 
(GRDF) will bring about new and important therapeutic options. For 
instance, they will significantly extend the period of time over which 
drugs may be released. The gastro retentive drug delivery systems 
can be retained in the stomach and assist in improving the oral 
sustained delivery of drugs that have an absorption window in a 
particular region of the gastrointestinal tract. These systems help in 
continuously releasing the drug before it reaches the absorption 
window, thus ensuring optimal bioavailability 
Drugs that are absorbed from the proximal part of the 
gastrointestinal tract (GIT). Local or sustained drug delivery to the 
stomach and proximal part of the small intestine to treat certain 
conditions. Particularly useful for the treatment of peptic ulcers 
caused by H. Pylori infections. The various pharmacokinetic 
advantages like maintenance of constant therapeutic level over a 
prolonged period of time and thus reduction in fluctuation in 
therapeutic levels minimizing the risk of resistance especially in the 
case of antibiotics [10-12]. 
For the present study Clarithromycin is selected as drug candidate 
to formulate floating tablets. Clarithromycin is (Chemical Name: 6-O-
methylerythromycin) a semi-synthetic broad spectrum macrolide 
antimicrobial agent. Clarithromycin is soluble in chloroform, 
acetone, and dilute acids. Slightly soluble in methanol, ethanol and 
acetonitrile, and practically insoluble in water. Clarithromycin is 
absorbed rapidly from the gastrointestinal tract after oral 
administration. Clarithromycin is used in combination for the 
treatment of Helicobacter pylori infection and duodenal ulcer 
disease and for treatment of upper and lower respiratory tract 
infections. Floating systems having low density systems that have 
sufficient buoyancy to float over the gastric contents and remain in 
the stomach for a prolonged period. While the system floats over the 
gastric contents, the drug is released slowly at the desired rate, 
which results in increased gastric retentive time and reduces the 
fluctuation in plasma drug concentration [13-15]. 
The major objective of the present work is to formulate, optimize 
and evaluate the floating tablets of Clarithromycin. Clarithromycin 
floating tablets are prepared by a conventional wet granulation 
method, by using sodium bicarbonate & citric acid as the gas 
generating agent and suitable polymer grade of HPMC.  
[5-9]. 
MATERIALS AND METHODS 
Materials 
Clarithromycin was received as a gift sample from Maxwell Life 
Science, Mumbai (India). Hydroxy propyl methylcellulose K-15M 
(HPMC-K100M) was supplied by Colorcon Asia Pvt Ltd (Goa, India) 
and Sodium bicarbonate, citric acid, magnesium stearate, talc were 
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purchased from Poona Chemicals Laboratories (Pune, India). PVP 
K30M was purchased from S. D Fine Chemicals Mumbai. All other 
ingredients were of analytical grade.  
Preparation of Clarithromycin floating tablets  
Floating matrix tablets containing Clarithromycin were prepared by 
wet granulation technique using varying concentrations of different 
grades of polymers with sodium bicarbonate. Polymers and 
Clarithromycin were mixed homogeneously using glass mortar and 
pestle. Isopropyl alcohol was used as granulating agent. Granules 
were prepared by passing the wet coherent mass through a # 16 
sieve. The granules were dried in hot air oven at a temperature of 60 °C 
for 1 hour.  
Dried granules were sieved through # 20 sieves and lubricated with 
magnesium stearate and talc just 4-5 min before compression. 
Lubricated granules were compressed using Karnavati Minipress 
tablet punching machine using 13 mm punches to obtain tablets of 
desired specifications [16, 17]. 
 
Table 1: Composition of Clarithromycin floating tablets 
Ingredients(mg.) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Clarithromycin 500 500 500 500 500 500 500 500 500 
HPMC K15M 75 100 125 75 100 125 75 100 125 
Sod. Bicarbonate 70 70 70 70 70 70 70 70 70 
Citric Acid 10 10 10 20 20 20 30 30 30 
PVP K30M 40 40 40 40 40 40 40 40 40 
Mg stearate 10 10 10 10 10 10 10 10 10 
Talc 5 5 5 5 5 5 5 5 5 
Total weight (mg) 710 735 760 720 745 770 730 755 780 
 
Full factorial design 
A 32 
 
randomized full factorial design was constructed to study. In 
this design 2 factors were evaluated, each at 3 levels and 
experimental, trials were performed at all 9 possible 
combinations.  
The amount of citric acid (X1) and HPMC K15M (X2) was selected as 
independent variables. The dependent variables chosen were 
percentage drug release at 6 hours (Q6), percentage drug release at 




 Factorial design of the formulation 
Batch code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
X -1 1 -1 -1 0 0 0 +1 +1 +1 
X -1 2 0 +1 -1 0 +1 -1 0 +1 
 
Table 3: Translation of coded values to actual values 
Coded values Actual values 
X X1 2 
-1 10 75 
0 20 100 
+1 30 125 
Where X1-Amount of citric acid, X2-Amount of HPMC K15 M., Q6-percentage drug release at 6 hours, Q12
 
Pre-compression evaluation 
Angle of repose 
The angle of repose of powder blend was determined by the funnel 
method. The accurately weight powder blend was taken in the 
funnel. The height of the funnel was adjusted in such a way the tip of 
the funnel just touched the apex of the powder blend. The powder 
blend was allowed to flow through the funnel freely on to the 
surface. The diameter of the powder cone was measured and an 
angle of repose was calculated using the following equation. 
tan 
-percentage drug release at 12hours, n-
diffusion coefficient. 
θ = H/R (Eq.1) 
Therefore, θ  = tan-1
Both loose bulk density (LBD) and tapped bulk density (TBD) was 
determined. A quantity of 2 gm of powder blend from each formula, 
previously shaken to break any agglomerates formed, was 
introduced in to 10 ml measuring cylinder. After that the initial 
volume was noted and the cylinder was allowed to fall under its own 
weight on to a hard surface from the height of 2.5 cm at second intervals. 
Tapping was continued until no further change in volume was noted. 
LBD and TDB were calculated using the following equations. 
LBD
 (H/R) (Eq.2) 
Where, h= height of the powder cone and r= radius of the powder 
cone. 
Bulk density 
 =         Weight of powder blend                                        (Eq.3) 
 Untapped volume of the packing 
 
TBD =         Weight of powder blend                           (Eq.4) 
                     Tapped Volume of the packing 
Compressibility index 
The Compressibility Index of the powder blend was determined by 
Carr’s compressibility index. It is a simple test to evaluate the LBD 
and TBD of a powder and the rate at which it packed down. The 
formula for Carr’s Index is as below:  
Carr’s index = TBD- LBD ×100      (Eq.5) 
TBD 
Hausner’s ratio (HR) 
This was calculated as the ratio of tapped density to bulk density of 
the sample 
HR =   Tapped Density       (Eq.6) 
Bulk Density 
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Post-compression evaluation of clarithromycin floating tablets 
Weight variation test 
To study the weight variation twenty tablets of the formulation were 
weighed using an electronic balance and the test was performed 
according to the official method. Twenty tablets were selected 
randomly from each batch and weighed individually to check for 
weight variation. 
Percentage Deviation PD =     Wavg -Winitial                                            (Eq.7) 
                        wavg 
Where,  
WAvg = average weight and 
WInitial  = initial weight 
Drug content 
Five tablets were weighed individually and powdered. The powder 
equivalent to average weight of tablets was weighed and the drug 
was extracted in 0.1N HCl. The drug content was determined 
measuring the absorbance at 288 nm after suitable dilution using a 
Simadzu UV-Visible double beam spectrophotometer 1800. 
Hardness 
Hardness indicates the ability of a tablet to withstand mechanical 
shocks while handling. The hardness of the tablets was determined 
using Pfizer hardness tester. It is expressed in kg/cm2. Three tablets 
were randomly picked and hardness of the tablets was determined. 
Thickness 
The thickness of the tablets was determined by using Vernier 
calipers. Five tablets were used, and average value was calculated. 
Friability test 
The friability of tablets was determined using Roche Friabilator. It is 
expressed in percentage (%). Ten tablets were initially weighed and 
transferred into Friabilator. The Friabilator was operated at 25 rpm 
for 4 minutes or run up to 100 revolutions. The tablets were 
weighed again. The % friability was then calculated by 
Percentage Friability =                  W-W0 × 100                                                              (Eq.  
W 
Where, W0
The in vitro buoyancy was determined by floating lag time method 
described by Dave B. S. The tablets were placed in 250 ml beaker 
containing 0.1 N HCl. The time required for the tablets to rise to the 
surface and float was determined as floating lag time. The time 
between introduction of the dosage form and its buoyancy in 0.1 N 
HCl and the time during which the dosage form remain buoyant was 
measured. The time taken for dosage form to emerge on surface of 
medium called Floating Lag Time (FLT) or Buoyancy Lag Time (BLT) 
and total duration of time by which dosage form remain buoyant is 
called Total Floating Time (TFT). 
= initially weight 
W= weight after friability 
Percentages Friability of tablets less than 1% are considered 
acceptable. 
In vitro buoyancy studies 
In vitro drug release study 
The release rate of from floating tablets was determined using The 
United States Pharmacopoeia (USP) dissolution testing apparatus II 
(paddle method). The dissolution test was performed using 900 ml 
of 0.1 N HCl, at 37±0.5 °C and 50 rpm. A sample (5 ml) of the 
solution was withdrawn from the dissolution apparatus hourly for 
12h, and the samples were replaced with fresh dissolution medium. 
The samples diluted with 2 ml Folin-Ciocalteu’s phenol reagent and 
2 ml of 20% sodium carbonate solution and 0.1N HCl up to 10 ml. 
Absorbance of these solutions was measured at 760 nm using a 
Simadzu UV-Vis double beam spectrophotometer. Cumulative 
percentage of drug release was calculated using the equation 
obtained from a standard curve. 
Swelling index of Clarithromycin floating tablets 
The swelling index of tablets was determined by using 0.1 N HCl (pH 
1.2) at room temperature. The swollen weight of the tablets was 
determined at predefined time intervals. The Swelling 
characteristics were expressed in terms of percentage water uptake 
(WU %) according to the equation 8. 
Weight of swollen tablet - Initial weight of tablet WU% = 100




RESULTS AND DISCUSSION 
In the present study, FDDS (Floating Drug Delivery System) of 
Clarithromycin were prepared by using polymer HPMC K15M, using 
sodium bicarbonate as gas generating agent and PVP K30 as binder. 
FDDS tablets were prepared by wet granulation technique. 
Formulation was optimized by using different ratios of polymers, 
citric acid. The prepared FDDS tablets were evaluated for its 
hardness, friability, uniformity of weight, uniformity of drug content, 
drug-polymer interaction studies, in vitro floating studies and in 
vitro dissolution studies.  
Full Factorial design 
A statistical model incorporating interactive and polynomial term 
was used to evaluate the responses. 
Y = b0+b1X1+b2X2+b11X12+b22X22+b12X1X
Where Y is the dependent variable, b
2 
0 is the arithmetic mean 
response of the 9 runs, and bi (b1, b2, b12, b11 and b22 is the 
estimated coefficient for the factor X1). The main effect (X1 and X2) 
represents the average results of changing one factor at a time from 
its low to high values. The interaction term (X1X2) showed how the 
response changes, when 2 factors are changed simultaneously. The 
polynomial term (X12 and X2 2
Table 4: Formulation and dissolution characteristics of batches in 3






Coded values % release at 6 hr (Q6 % release at 12hr (Q) 12 n value ) 
X1 X2 
F1 -1 -1 46.038 97.766 0.9996 
F2 -1 0 50.324 93.945 0.7706 
F3 -1 +1 55.797 83.321 0.5807 
F4 0 -1 52.337 89.753 0.8217 
F5 0 0 50.215 80.738 0.8127 
F6 0 +1 43.993 76.859 0.9324 
F7 +1 -1 57.879 85.006 0.5614 
F8 +1 0 53.220 78.187 0.6708 
F9 +1 +1 51.105 72.675 0.7290 
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Table 5: Multiple Regressions output for dependent variables 
Parameters b0 b1 b2 b11 b22 b12 R2 
Q6 49.7606 2.3276 -0.8932 4.1990 -1.3685 -3.9199 0.75963 
Q12 82.4081 -6.5888 -6.6117 2.6386 0.0629 0.3686 0.97623 
 n value 0.8118 -0.0881 -0.0234 -0.160 0.0657 0.1387 0.87489 
 
The responses of formulation prepared by 32factorial designs are 
indicated in table 6 The data clearly indicate that the Q6, Q12 and 
diffusion exponent (n) are strongly dependent on the selected 
independent variables. The fitted equation relating the response Q6, 
Q12 and diffusion exponent (n) to the transformed factors are shown 
in equation 10, 11 and 12 respectively.  
Q6 = 49.76+2.32X1–0.89X2+4.19X12-1.36X22-3.91X1X2 (Eq.10) 
(R2 = 0.7596) 
Q12 = 82.40-6.58X1-6.61X2+2.63 X12+0.06X22
(R
+0.36 X1X2 (Eq.11) 
2
n = 0.81-0.08 X1-0.02 X2-0.16 X1
= 0.97623) 
2+0.06 X22+0.13 X1X2 (Eq.12)  
(R2= 0.87489)  
The polynomial equation can be used to draw conclusion after 
considering the magnitude of coefficient and the mathematical sign 
it carries, (i.e., positive or negative). Positive or negative signs before 
a coefficient in quadratic models indicate a synergistic effect or an 
antagonistic effect for the factor. The high values of correlation 
coefficient (table 6) for Q6 (R2 = 0.7596), Q12 (R2= 0.9762), n (R2= 
0.8748) indicate a good fit.  
Equation no 10 for Q6 showed b1 & b11 positive but b2, b12 & b22 
negative this reveals that up to certain level increases in X1 and 
X12from-1 to+1 increases Q6 after that point again decreases in Q6 
seen. Percentagerelease at 6 hr (Q6) was found to be 46.038 to 
57.879 for batches containing X2 at-1 level, 43.993 to 55.797 to for 
batches containing X2+1 level, 50.215 to 53.22 for batches 
containing X2 at 0 level. 
Equation no 11 for Q12 showed b12, b11 & b22 positive but b1 & b2 
negative this revails that up to certain level increases in X1, X2, 
X12and X22from-1 to+1 increases Q12. Percentagerelease at 12 hr 
(Q12) was found to be 85.006 to 97.766 for batches containing X2 at-
1 level, 72.675 to 83.321 for batches containing X2+1 level, 78.187 to 
93.945 for batches containing X2 at 0 level. 
Equation no 12 for n showed b12 & b22 positive, but b1, b2 & b11 
negative this reviles that up to certain level increases in X12 and 
X22from-1 to+1 increases n. Value of diffusion exponent (n) was 
found to be 0.5614 to 0.9996 for batches containing X2 at-1 level, 
0.5807 to 0.9324 to for batches containing X2+1 level, 0.6708 to 
0.8127 for batches containing X2 at 0 level. 
The main effects (X1 and X2) represents the average result of 
changing one factor at a time from its low to high value. The 
interaction terms (X1, X2, X1X2, X12, X22
Fig. 1, 2 and 3 show the plot of the amount of citric acid (X1) and an 
amount of HPMC K15M (X2) versus Q6, Q12, and diffusion exponent 
(n) respectively. The plot was drawn using PCP-Dissso v 3software, 
India. The data demonstrate that both X1 and X2 affect the drug 
release (Q6, Q12 and diffusion exponent (n)). 
) shows the response changes 
when two or more factors are simultaneously changed.  
The equation for Q6 (Eq 10) suggested that the factor X1 has the 
more significant effect on drug release at Q6, therefore high level of 
factor is not selected for increasing drug release. From equation 11 
it can conclude that single factor X1 not more effect on Q12, but factor 
in combination X1 and X2 shows positive effect.  
It means that the when the value of X2 increases Q12 decreases. From 
equation 12 negative sign of X1 it concludes that diffusion exponent 
not depend on the value of X1 but the magnitude of coefficient 
indicates that the factor X2 has the more favorable effect on the 
dependent variables. 
 
Fig. 1: Response surface plot for Q6 
 
 
Fig. 2: Response surface plot for Q12 
 
 
Fig. 3: Response surface plot for diffusion exponent (n) 
 
It may also be concluded that the low level of X1 (amount of citric 
acid) and the higher level of X2 (amount of HPMC K15M) positive 
effect on diffusion exponent (n) favor the preparation of floating 
sustained release Clarithromycin tablets. The high value of X1X2 
coefficient also suggests that the interaction between X1 and X2 has a 
significant effect on Q12. It can be concluded that the drug release 
pattern may be changed by appropriate selection of the X1 and X2 
levels. An increase in the concentration of citric acid (X1) and 
amount of HPMC K15M (X2), increase and decrease rate of release of 
Clarithromycin floating tablet respectively.  
Fig. 1 shows the influence of content of HPMC K15M and citric acid 
on Q6. It was found that percentage drug release increase with 
decreases in content of HPMC K15M and citric acid. Although the 
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content of HPMC K15M and citric acid significant influence on the Q6 
it ranged from 43.99–57.87. From the graph, it is observed that 
percentage drug release at 6 hr (Q6) is increases. 
Fig. 2 shows multiple regressions analysis for percentage drug release 
at 12 hr (Q12) showed the significant contribution of both the factors 
on the response. Increasing the concentration of polymer (X2) and 
citric acid (X1) retardation of the drug release at Q12 is observed. 
Fig. 3 shows the influence of content of HPMC K15M and citric acid 
on diffusion exponent. It was found that diffusion exponent rises 
with increase with content of HPMC K15M and citric acid. When the 
concentration of polymer is increased, the release of the drug tends 
to become slower. Although the content of HPMC K15M and citric 
acid significant influence on the diffusion exponent it ranged from 
0.5614-0.9996, indicating anomalous drug release. Regarding the 
overall effect of both factors, it appeared that the diffusion exponent 
was affected more by the content of HPMC K15M, when 
concentration of polymer increases diffusion exponent decreases. 
Evaluation of granules 
Angle of repose (θ) 
The angle of repose for the formulated blend was carried. Values of 
angle of repose ≤30⁰ generally indicate the free flowing material and 
angle of repose ≥40⁰
Carr’s index below 15 % usually shows good flow characteristics, 
but above 25% indicates poor flowability. Compressibility index was 
carried out, it found between 9.52% and 15.90% indicating the 
powder blend has the required flow property for compression.  
 suggest a poor flowing material. The angle of 
repose of all the formulations fell within the range of 24 °.22' to      
27 °.75'. Compressibility index 
Hausner’s ratio 
Hausner’s ratio is the simple method to evaluate stability of powder 
column and to estimate flow properties. Low range was observed for 
Hausner’s ratio that indicates good flow ability. Many different types 
of angular properties have been employed to assess flowability. The 
Hausner’s ratio was found between 1.10 and 1.18. 
Bulk density & tapped density 
Bulk density may influence compressibility, tablet porosity, 
dissolution and other properties and depends on the particle size, 
shape and tendency of particles to adhere together. The bulk density 
of granules was found to be between 0.31 to 0.37 g/cm3 (Table.7). 
This indicates good packing capacity of granules. Bulk density and 
tapped density measurements found that density of a powder 
depends on particle packing and that density changes as the powder 
consolidates. The degree of consolidation is unique to the powder 
and ratio of these densities is related to interparticulate friction. 
 
Table 6: Micrometric properties of powder blend 








FT-1 24.22 0.37 0.44 1.18 15.90 
FT-2 24.44 0.36 0.40 1.11 10.00 
FT-3 26.67 0.34 0.38 1.10 9.52 
FT-4 24.30 0.37 0.42 1.11 10.638 
FT-5 25.19 0.35 0.39 1.10 9.580 
FT-6 26.56 0.33 0.385 1.15 13.065 
FT-7 25.11 0.36 0.42 1.15 13.095 
FT-8 25.9 0.34 0.39 1.15 13.66 
FT-9 27.75 0.31 0.35 1.13 11.98 
 
Evaluation of tablets  
Hardness and friability  
Thus, the tablets found to be of good tensile strength to withstand 
the handling stress without break. Tablets hardness is a determining 
factor, with regard to the buoyancy of the tablets. Tablet hardness 
reflects differences in tablet density and porosity, which are 
supposed to result in difference release patterns of the drug by 
affecting the rate of penetration of the dissolution fluid at the surface 
of the tablet.  
The hardness of the prepared GFDDS of Claritromycin was found to 
be in the range of 5.1 to 5.4 kg/cm2
Uniformity of weight 
 and is given in table 7. It ensures 
that the tablets can withstand mechanical impacts during packing, 
transportation and other processing operations. The present study 
of tablets is in within the limit and the slight variation in friability 
because of the variation in the compression force applied and its 
total weight. The friability of tablets is also depends on the moisture 
contents in it. The friability of all the tablets was to be less than 1% 
i.e. in the range of 0.79 to 0.99% given in table 7. 
All the prepared GFDDS tablets were evaluated for weight variation 
and the results are given in table 7. The percent deviation from the 
average weight was found to be within the prescribed official limits.  
Uniformity of drug content  
The drug content uniformity was examined as per I. P specification. 
All the batches of tablets were found to comply with uniformity of 
content test and results are mentioned in table 7. Drug content was 
in the range of 94.66±0.57% to 97.66±0.57% in the prepared 
formulation.
 




Averagewt in (mg)±SD 




Friability (%) Drug Content 
Uniformity (%)±SD 
F-1 708±1.15 5.2±0.25 5.10±0.10 0.87 97.66±0.57 
F-2 735±2.08 5.2±0.3 5.10±0.20 0.81 96.66±1.52 
F-3 759±1.52 5.3±0.25 5.16±0.05 0.92 96.66±2.08 
F-4 718±1.52 5.4±0.25 5.23±0.11 0.83 97.66±0.57 
F-5 743±0.57 5.3±0.30 5.30±0.10 0.99 97.00±1.00 
F-6 770±2.0 5.2±0.17 5.06±0.15 0.90 94.66±0.57 
F-7 732±3.05 5.5±0.20 5.13±0.15 0.82 98.66±0.57 
F-8 754±0.57 5.1±0.17 5.13±0.11 0.79 96.66±0.57 
F-9 778±0.57 5.3±0.20 4.93±0.15 0.89 94.66±2.08 
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In vitro buoyancy 
The gas generated is trapped and protected within the gel, formed 
by hydration of polymer, thus decreasing the density of the tablet. As 
the density of the tablet falls below 1, the tablet became buoyant. 
The results presented in table 8. reveled that HPMC K15M produced 
tablets with good gel strength, entrapping CO2 gas and imparting 
stable and persistent buoyancy. Floating lag time was in range of 20 
sec to 45 sec. All the factorial design batches showed good in vitro 
buoyancy, also the tablet remained buoyant for 12 hours, but the 
tablet actually floated throughout the entire study. The above 
photograph of in vitro buoyancy study the optimized batch F1 tablet 
at initial 0 min seen at the bottom of beaker, at the 20 sec the tablet 
was seen at center of the beaker that is the floating lag time and at 1 
min the tablet was seen at surface of the beaker. 
 
Table 8: Floating properties of clarithromycin floating tablets 






 F1 20   >12 
F2 22   >12 
F3 28   >12 
F4 25   >12 
F5 25   >12 
F6 30   >12 
F7 45   >12 
F8 35   >12 
F9 28   >12 
 
Swelling study  
The swelling indexes of batches F1 to F9 are shown in fig. 4. Polymer 
matrices representing swellable matrix drug delivery systems are 
porous in nature. When these matrices come in contact with water 
or aqueous gastrointestinal fluid, the polymer absorbs the water and 
undergoes swelling or hydration. The rapid formation of a viscous 
gel layer upon hydration suggests that swelling is associated with 
polymer chain relaxation with volume expansion. The liquid diffuses 
through the polymer matrix at a constant velocity, and the rate of 
diffusion of the liquid and that of macromolecular relaxation of the 
polymer are almost of the same magnitude or, possibly, the rate of 
diffusion of the liquid is relatively higher than that of relaxation of 
the polymer segment. 
This mechanism gives the idea regarding the water uptake study of 
various grades of polymer. This phenomenon is attributes to that the 
swelling is more due to water uptake and then gradually decreased 
due to erosion. Swelling measurement was performed separately in 
order to collect on the basis of weight increase over time. The 
swelling is due to presence of hydrophilic polymer, which gets 
wetted and allows water uptake leads to increase in its weight.  
The swelling index was calculated with respect to time. As time 
increase, the swelling index was increased, because weight gain by 
tablet was increased proportionally with rate of hydration. Later on, 
it decreased gradually due to dissolution of outermost gelled layer of 
tablet into dissolution medium. The direct relationship was 
observed between swelling index and HPMC K15M increase, 
swelling index was increased. 
 
 
Fig. 4: Relationship between swelling index and time 
 
In vitro dissolution study  
Besides the satisfactory buoyancy, the matrix tablets are required to 
release Clarithromycin gradually over prolonged period. Hence, they 
were tested for release kinetics by conducting in-vitro dissolution 
test. 
From the dissolution study it was concluded that release from the 
matrix is largely dependent on the polymer swelling, and drug 
diffusion. It was observed that all the tablets ascended to the upper 
one third of the dissolution vessels within a short time, and 
remained floated until the complete of release studies. The drug 
release study was carried out up to 12 hrs. The percentage drug 
release from batch F1 to F9 vary from 97.76 to 72.67% because of 
increase in concentration of polymer (HPMC K15M). High drug 
release is observed in F1 batch because of low concentration of 
polymer (HPMC K15M).  
Large concentration of high viscosity polymer induces the formation 
of strong viscous gel layer that slowed down the rate of water 
diffusion into the tablet matrix, which may result in the retardation 
or decreases the drug release. Being water soluble polymers, they 
dissolve and form pores filled liquid in which drug can there after 
diffuse in dissolution medium. All the formulations were designed as 
dosage form for 12 hrs. Dissolution profiles of all batches were 
shown in fig. 5. From the dissolution study it was concluded that 
release from the matrix is largely dependent on the polymer 
swelling, drug diffusion. 
 
 
Fig. 5: In vitro release profile of clarithromycin all formulation 
 
CONCLUSION 
The present work was formulation, optimization and evaluation of 
floating tablet of Clarithromycin. Clarithromycin floating tablet is 
promising approach to achieve in vitro buoyancy by using 
hydrophilic polymer HPMC K15M and gas generating agent sodium 
bicarbonate and citric acid. A systemically study using a 32
Thus, formulation F1 was selected as an optimized formulation 
because it gave the best results in terms of the required in vitro 
buoyancy study (Floating lag time 20 sec, Total floating time 12 




factorial design revealed that the amount of citric acid (X1) and 
amount of hydroxy propyl methylcellulose (HPMC K15M) (X2) had a 
significantly effect on Q6, Q12 & diffusion exponent (n).  
Decreased in citric acid concentration in formulation showed 
decreased in drug release, this is due to citric acid reaction with 
sodium bicarbonate resulting generation of carbon dioxide gas at a 
faster rate, increased rate of drug release. Increasing the 
concentration of HPMC K15M resulted in reduction of drug release. 
The formulation was optimized on the basis of floating ability, 
matrix integrity and in vitro drug release.  
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